| abstract |
The invention relates to compounds of formula (I) wherein Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl containing one, two or three nitrogen atoms and wherein the aryl and heteroaryl groups may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, CN, (C1-C6) alkyl, (C1-C6) alkyl substituted by halogen, (C1-C6) alkoxy, (C1-C6) alkoxy substituted by halogen, NR7R8, C (O) R9 or SO2R10; R 1 is hydrogen or (C 1 -C 6) alkyl; R2 is halogen, (C1-C6) -alkyl, (C2-C6) -alkenyl, where a hydrogen atom may be replaced by CN, C (O) -R9 or (C1-C6) -alkyl or is (C2-C6) -alkynyl, (C1-C6) -alkyl substituted with halogen, - (CH2) n- (C3-C7) -cycloalkyl, - (CH2) n-heterocycloalkyl, -C (O) -R9, - (CH2) n- aryl or - (CH2) n-5- or 6-membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulfur or nitrogen wherein aryl, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (C1-C6) -alkyl, (C1-C6) -alkyl substituted by halogen or (C1-C6) -alkoxy; R 3, R 4 and R 6 are independently hydrogen, hydroxy, halogen, (C 1 -C 6) alkyl or (C 1 -C 6) alkoxy; R5 is NO2, CN, C (O) R9, SO2R10 or NR11R12; R7 and R8 are independently hydrogen or (C1-C6) alkyl; and the other substituents are as defined in the claims; and pharmaceutically acceptable acid addition salts thereof for the treatment of psychoses, pain, neurodegenerative memory and learning dysfunction, schizophrenia, dementia, and other disorders in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease. |